1. Preferences for a Clostridioides difficile vaccine among adults in the United States.
- Author
-
Vietri J, Maculaitis MC, Cappelleri JC, Yu H, Kopenhafer L, and Beusterien K
- Subjects
- Humans, Middle Aged, Female, United States, Male, Cross-Sectional Studies, Aged, Vaccination psychology, Patient Preference statistics & numerical data, Surveys and Questionnaires, Aged, 80 and over, Bayes Theorem, Clostridium Infections prevention & control, Bacterial Vaccines administration & dosage, Bacterial Vaccines immunology, Bacterial Vaccines economics, Clostridioides difficile immunology
- Abstract
Introduction: Clostridioides difficile (C.diff) infection (CDI) causes significant morbidity and mortality among older adults. Vaccines to prevent CDI are in development; however, data on the target population's preferences are needed to inform vaccination recommendations in the United States (US). This study assessed US adults' willingness to receive a C.diff vaccine and examined how vaccine attributes influence their choices., Methods: A cross-sectional online survey with a discrete choice experiment (DCE) was conducted among US adults aged ≥50 years. DCE attributes included effectiveness, duration of protection, reduction in symptom severity, out-of-pocket (OOP) costs, number of doses, and side effects. The DCE included 11 choice tasks, each with two hypothetical vaccine profiles and an opt-out (i.e., no vaccine). Attribute-level preference weights were estimated using hierarchical Bayesian modeling. Attribute relative importance (RI) was compared between select subgroups., Results: Of 1216 adults in the analyses, 29.9% reported they knew either 'a little' (20.7%) or 'a lot' (9.2%) about C.diff before the study. A C.diff vaccine was chosen 58.0% of the time (vs. opt-out) across choice tasks. It was estimated that up to 75.0% would choose a vaccine when OOP was $0. Those who were immunocompromised/high-risk for CDI (vs. not) more frequently chose a C.diff vaccine. Decreases in OOP costs (RI = 56.1), improvements in vaccine effectiveness (RI = 17.7), and reduction in symptom severity (RI = 10.3) were most important to vaccine choice. The rank ordering of attributes by importance was consistent across subgroups., Conclusion: OOP cost, improvements in vaccine effectiveness, and reduction in CDI severity were highly influential to vaccine selection. Most adults aged ≥50 years were receptive to a C.diff vaccine, especially with little-to-no OOP cost, suggesting that mandating insurance coverage of vaccination with no copayment may increase uptake. The limited awareness about C.diff among adults presents an opportunity for healthcare providers to educate their patients about CDI prevention., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jeffrey Vietri reports financial support was provided by Pfizer Inc. Jeffrey Vietri reports a relationship with Pfizer Inc. that includes: employment and equity or stocks. Joseph C. Cappelleri reports a relationship with Pfizer Inc. that includes: employment and equity or stocks. Holly Yu reports a relationship with Pfizer Inc. that includes: employment and equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Pfizer Inc. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF